- Indivior said Monday a US court had granted a preliminary injunction against Dr. Reddy's Laboratories, preventing the sale of a generic version of the company's opioid addiction treatment.

As the restrictions of Indivior's previously entered temporary restraining order remained in place, Dr. Reddy's Laboratories would be unable to sell, offer to sell, or import its generic opioid addiction treatment.

The US District Court for the District of New Jersey had also ordered Indivior to post a bond to provide security to Dr. Reddy's Laboratories should the court conclude at the end of patent litigation that the '305 patent is invalid or not infringed.

Prior to the granting of a temporary restraining order on 15th June, Dr.Reddy's Laboratories had sold a quantity of its generic buprenorphine, or naloxone sublingual film into the US market, Indivior confirmed.

The launch of generic versions for Indivior's Suboxone Film is expected to reduce full-year 2018 net revenue by least $25m.

The Court also ordered the parties to submit a final proposed injunction order by Monday, July 16.

'As a result of the July 13th court ruling, Dr. Reddy's is prevented from re-launching its generic product until the patent litigation related to the '305 patent is concluded or until DRL prevails on an appeal of this injunction. While we do not know the timing for these events, we will continue to vigorously defend our intellectual property,' said Shaun Thaxter, CEO of Indivior. Story provided by